Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: No accentuation by apolipoprotein(a)-Reference-Cited by-同舟云学术

Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: No accentuation by apolipoprotein(a)

Published:1998-04-14 Issue:8 Volume:95 Page:4544-4549
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Sanan D. A.,Newland D. L.,Tao R.,Marcovina S.,Wang J.,Mooser V.,Hammer R. E.,Hobbs H. H.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference29 articles.

1. Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E

2. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells

3. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

4. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression.

5. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption.

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review on in-vivo and in-vitro Models of Obesity and Obesity-Associated Co-Morbidities;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-08-12

2. Considerations for choosing an optimal animal model of cardiovascular disease;Canadian Journal of Physiology and Pharmacology;2024-02-01

3. High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner;Atherosclerosis;2023-11

4. Mapping the aetiological foundations of the heart failure spectrum using human genetics;2023-10-03

5. Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery;Clinical Science;2022-12